Medicare, commercial plans, and Medicaid: which medications are covered and how to check your coverage.
Insurance coverage for GLP-1 medications varies significantly. It's one of the most confusing aspects of GLP-1 access. The landscape has shifted dramatically between 2024 and 2026, with Medicare expanding coverage and more commercial insurers adding weight loss drugs to their formularies. This guide walks you through what's covered, how to verify your benefits, and what options exist if your plan says no.
As of early 2026, the GLP-1 insurance situation breaks down into three clear tiers:
Tier 1 (Widely Covered): GLP-1s for type 2 diabetes. Ozempic, Mounjaro, and generic/compounded semaglutide are covered by most commercial plans and Medicare Part D, though prior authorization is standard.
Tier 2 (Expanding): GLP-1s for weight loss. Wegovy and Zepbound coverage has grown from almost zero in 2024 to roughly 30-40% of commercial plans in 2026. This is the fastest-changing category.
Tier 3 (Plan-Specific): Medicaid coverage for either indication. Policies vary dramatically by state, with some covering both indications and others covering neither.
Most commercial insurance and Medicare cover GLP-1s for diabetes. Weight loss coverage is expanding but still inconsistent. Prior authorization is nearly always required. Medicaid varies by state.
About 85% of Americans under 65 have commercial insurance through an employer or ACA marketplace. Coverage for GLP-1s depends on several factors:
1. The indication (reason for use): Diabetes coverage is standard. Weight loss coverage is growing but not universal. Some plans explicitly exclude anti-obesity medications.
2. Your specific plan's formulary: Even within the same insurer, different plans have different drug lists. A gold plan might cover Wegovy while a bronze plan doesn't.
3. Prior authorization: Nearly 100% of commercial plans require prior authorization for GLP-1s. This is not optional; you need it approved before filling the prescription.
4. Brand vs. compounded: Brand-name Ozempic is more commonly covered than Wegovy for weight loss. Compounded semaglutide sits in a gray area—some plans cover it, others don't. GLP-1 compounding is less regulated than brand-name drugs, so coverage varies widely.
Covered by approximately 90% of commercial plans for type 2 diabetes. Prior authorization is standard but approval timelines are usually 3-5 business days. Some plans may require documentation that you've tried metformin first (step therapy). Cost: typically $0-100 copay after meeting deductible, depending on plan.
Coverage has expanded from about 5% of plans in 2023 to roughly 35-40% in 2026, driven partly by employer demand and partly by increasing clinical evidence of cardiovascular benefits. However, many plans still exclude weight loss medications outright. Those that cover Wegovy often require: documented BMI over 27-30, failed diet/exercise attempts, or weight-related comorbidities (diabetes, hypertension, sleep apnea). Prior authorization timelines: 5-14 days. Cost varies: some plans cover it at standard copay; others place it in a specialty tier ($100-250+ per month). Check your specific formulary.
Mounjaro is covered by approximately 80% of commercial plans for type 2 diabetes. Zepbound coverage lags Wegovy slightly—roughly 25-30% of plans cover it. Both typically require prior authorization. Some plans prefer Mounjaro over Wegovy due to Eli Lilly pricing agreements. If your plan covers tirzepatide, Mounjaro usually has better coverage than Zepbound, even though they're the same drug.
Medicare's coverage of GLP-1s has undergone a seismic shift. Historically, Medicare explicitly excluded weight loss drugs under the Social Security Act. But two major policy changes in 2024-2025 changed this:
The Treat and Reduce Obesity Act: Pending legislation that would remove the federal weight loss exclusion from Medicare coverage. While not yet fully enacted, CMS has been granting plan-by-plan exceptions since late 2024.
The Inflation Reduction Act (IRA): Signed in 2022, it gradually allowed Medicare to negotiate drug prices and funded expanded coverage options. By 2026, several Medicare Part D plans now cover GLP-1s for weight loss in beneficiaries with obesity and related conditions (cardiovascular disease, type 2 diabetes, sleep apnea). However, this varies by plan and state.
Current Medicare coverage (2026):
If you're on Medicare and your plan doesn't cover the medication you want, you can switch plans during the annual open enrollment period (October 15-December 7). Many beneficiaries don't realize they can change to a plan that covers GLP-1s.
Check CMS.gov or call 1-800-MEDICARE to see which Part D plans in your state cover GLP-1s for your specific indication. Open enrollment happens every October; if your current plan doesn't cover it, switch to one that does.
Medicaid is jointly funded by federal and state governments, which means each state sets its own coverage policies. There is no single "Medicaid coverage" for GLP-1s—it depends entirely on where you live.
State-by-state overview:
Contact your state Medicaid program directly or visit medicaid.gov to check your state's current policy. If you're on Medicaid and your state covers GLP-1s, prior authorization is almost always required.
Prior authorization is the #1 hurdle you'll encounter. Nearly every insurance plan—commercial, Medicare, and Medicaid—requires it for GLP-1s.
What is it? Your doctor submits proof to your insurance company that the medication is medically necessary before you fill the prescription. The insurer reviews the information and either approves it, denies it, or requests more information.
Why require it? Insurance companies use prior authorization to control costs, prevent overuse, and ensure the medication matches the patient's diagnosis. For GLP-1s, they're checking that you have type 2 diabetes or obesity plus comorbidities.
What's the timeline? Standard turnaround is 3-5 business days for diabetes indications, 5-14 days for weight loss indications (because the criteria are more stringent). Some urgent requests can be approved same-day. During holidays, expect delays.
What does your doctor need to provide? Typically:
Most doctors' offices handle prior auth requests automatically, but if your doctor is slow, ask to escalate the request.
Many insurers, particularly for weight loss coverage, require "step therapy." This means they want documentation that you've already tried and failed other treatments before approving GLP-1.
For diabetes: Step therapy is less common but still used. Some plans require documentation that you've tried metformin (a cheaper first-line drug) first.
For weight loss: Step therapy is standard. Insurers want evidence that you've attempted:
Your doctor can usually document this without a formal "program"—they can document your own efforts. But some insurers require enrollment in a formal weight loss program. If you're seeking coverage for weight loss, ask your doctor upfront about step therapy requirements for your specific plan.
While policies change frequently, here are current general trends (2026) from the largest commercial insurers:
UnitedHealthcare: Covers Ozempic for diabetes across most plans (prior auth required). Wegovy coverage is available but varies by plan; typically requires BMI ≥30 and documented comorbidities. Approval timeline: 5-7 days.
Cigna: Covers Ozempic and Mounjaro for diabetes. Wegovy coverage is offered in select plans, usually with higher copays ($150-200/month). Step therapy often required.
Aetna (CVS Health): Covers both semaglutide and tirzepatide for diabetes. Expansion into weight loss coverage is ongoing. Copays range $25-100 depending on plan tier.
Blue Cross Blue Shield (varies by state): Most state Blue plans cover Ozempic for diabetes. Weight loss coverage varies by state plan. Contact your specific state BCBS plan for clarity.
Anthem: Similar to BCBS; covers Ozempic for diabetes. Wegovy coverage depends on specific plan and state regulations.
Humana: Covers Ozempic for diabetes. Expanding weight loss coverage as of 2026.
None of these generalizations are absolute—your specific plan can differ. Always call your insurer's member services line to verify coverage for your exact plan.
If your insurance doesn't cover GLP-1s, you have several financial options:
Retail prices (brand-name): Ozempic, Wegovy, Mounjaro, and Zepbound cost $900-1,500/month at retail without insurance. This is the uninsured, full manufacturer list price.
Manufacturer savings programs:
Compounded semaglutide: A major alternative to brand-name Ozempic/Wegovy. GLP-1 compounding pharmacies prepare semaglutide from bulk powder at a fraction of brand-name cost: typically $150-350/month. Quality and consistency vary by pharmacy. Make sure any compounded GLP-1 comes from a licensed, accredited compounding pharmacy (ask to verify PCAB or NABP accreditation). Some insurers cover compounded versions; others don't.
Telehealth GLP-1 programs: Companies like Ro, Found, Calibrate, Hims, and others offer GLP-1s through direct-to-consumer telehealth. They bypass traditional insurance and use manufacturer discounts + volume purchasing to reduce costs. Typical prices: $150-300/month for compounded semaglutide, $400-600/month for brand-name Mounjaro. These programs handle the clinical side (prescription, dosage management) but don't require insurance. See the /reviews/ section of our site for detailed comparisons.
Patient assistance programs (PAP): Novo Nordisk and Eli Lilly both offer patient assistance for uninsured or underinsured patients below certain income thresholds. These programs can reduce cost to $0. Eligibility: typically household income below 200-400% of federal poverty line. Ask your doctor to apply, or visit the manufacturer's website.
| Option | Cost/Month | Pros | Cons |
|---|---|---|---|
| Brand-name Ozempic (retail) | $900-1,200 | Guaranteed supply, FDA-approved | Very expensive |
| Novo Nordisk savings card | $0-250 | Easy to use, immediate savings | Requires insured or PAP eligibility |
| Compounded semaglutide | $150-350 | Affordable, available | Inconsistent quality, unregulated |
| Telehealth program (Ro, Found, etc.) | $150-600 | No insurance needed, convenient | May not be covered by insurance |
| Medicare (Part D copay) | $10-100 | Lowest out-of-pocket | Requires Medicare eligibility |
Insurance denials happen. If your claim for prior authorization is denied, you have rights.
Step 1: Understand the denial. Read the denial letter carefully. It will state the reason—usually "not medically necessary," "excluded indication," or "step therapy not met."
Step 2: Ask your doctor to appeal. Most appeals are successful when a doctor submits additional clinical evidence. Examples:
Step 3: File a formal appeal. Most insurers allow two levels of appeal: internal (medical review by the insurer) and external (review by an independent third party). The appeal process timeline is typically 15-30 days for internal appeals, 30 days for external.
Success rates: Appeals have a surprisingly high success rate. Studies show 40-60% of initial denials are overturned on appeal, particularly if your doctor submits clinical justification. For GLP-1s specifically, denials are often due to administrative errors or missing information rather than clinical reasons.
External appeals: If the insurer denies the internal appeal, you can request an external independent review. This involves a neutral medical reviewer (not employed by the insurer) evaluating your case. External reviews have higher success rates (50-70%) because the reviewer is independent.
Don't accept an initial denial as final. Work with your doctor to submit an appeal with clinical justification. Many people get approved on the second or third try. The insurer is betting you won't appeal.
As of 2026, large employers are increasingly adding GLP-1 coverage to their health plans to manage healthcare costs and attract talent. This is a relatively new trend—in 2023, almost no employers covered GLP-1s for weight loss.
Early adopters (2025-2026): Costco, Walmart, Tesla, and several Fortune 500 companies have added GLP-1 coverage for weight loss or diabetes management in their employee plans. Some employers are even subsidizing the cost as a wellness benefit.
Trend direction: Expect coverage to expand. Employers are noticing that GLP-1s reduce long-term healthcare costs by preventing diabetes complications and cardiovascular disease. A few employers have even partnered with telehealth GLP-1 programs to offer in-network discounts.
If you're considering a job change, ask whether the company's health plan covers GLP-1s—it's becoming a competitive benefit.
Good news: GLP-1 medications prescribed for diabetes or medically-necessary weight loss are eligible for Flexible Spending Accounts (FSA) and Health Savings Accounts (HSA).
FSA: If you have an employer-sponsored FSA, you can use pre-tax dollars to pay for GLP-1s (both the medication and any telehealth fees). Maximum annual contribution: $3,300 (2026).
HSA: If you're enrolled in a high-deductible health plan (HDHP), you can contribute to an HSA and use funds to pay for GLP-1s, compounding pharmacy fees, and even telehealth programs. Maximum contribution: $4,300 (individual) / $8,550 (family) per year (2026).
This can significantly reduce your out-of-pocket cost if you have pre-tax savings accounts available through your employer.
Yes, with about 90% probability. Most commercial plans and Medicare cover Ozempic for type 2 diabetes. Prior authorization is required, but approval timelines are typically 3-5 days. Call your insurer's member services line to confirm your specific plan covers it.
Possibly. Coverage has expanded significantly—roughly 35-40% of commercial plans now cover Wegovy for weight loss (as of 2026), up from nearly zero in 2024. You'll need to meet your plan's criteria: usually BMI over 27-30, documented failed diet/exercise attempts, and possibly weight-related conditions like diabetes or hypertension. Prior authorization is required; typical timeline is 5-14 days. Check your plan's formulary online or call member services.
Same medication (semaglutide), different indications. Ozempic is FDA-approved for type 2 diabetes; Wegovy is FDA-approved for weight loss. Insurance coverage differs because insurers treat them as different products. Many plans cover Ozempic for diabetes but not Wegovy for weight loss. If your plan covers Ozempic but not Wegovy, ask your doctor about using Ozempic off-label for weight loss (it's medically equivalent and often covered).
Standard timeline: 3-5 business days for diabetes indications, 5-14 days for weight loss indications. Urgent/expedited requests can sometimes be approved same-day. Holiday periods and plan-specific delays can extend this. Ask your doctor to file the request ASAP and follow up if you don't hear back within 7 days.
Step therapy means your insurer wants evidence that you've tried other treatments first. For diabetes, it's less common; they might require proof you tried metformin. For weight loss, it's standard—they'll want documentation of diet and exercise attempts. Your doctor can usually document this without a formal program. If your plan requires step therapy, ask your doctor for guidance on what to document.
Don't accept it as final. Have your doctor submit an appeal with updated clinical evidence (recent A1C, BMI, comorbidity documentation). Internal appeals succeed about 40-60% of the time. If the internal appeal fails, request an external independent review—these succeed 50-70% of the time. The appeals process typically takes 15-30 days.
Brand-name medications: $900-1,500/month retail. But there are cheaper options: manufacturer savings cards ($0-400/month), compounded semaglutide ($150-350/month), telehealth programs ($150-600/month), and patient assistance programs (up to free if income-qualified). Check all these options before paying retail price.
Compounded semaglutide is legal and safe if sourced from an accredited pharmacy. Ask your pharmacy if they're PCAB or NABP-accredited. Cost is significantly lower ($150-350/month) than brand-name, but consistency can vary. Some insurers cover compounded versions; others don't. Cost is similar whether insured or uninsured.
Yes. GLP-1 medications are eligible expenses for both FSA and HSA accounts. This means you can pay with pre-tax dollars, reducing your out-of-pocket cost by your effective tax rate (typically 20-40%). Check with your plan's administrator if you're unsure.
Yes. Medicare Part D open enrollment happens October 15-December 7 each year. You can switch to a different Medicare Advantage or Part D plan if your current plan doesn't cover the GLP-1 you want. Use Medicare.gov's plan finder to see which plans in your state cover GLP-1s for your indication.
Not sure which program is right for you?